Trial Profile
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2021
Price :
$35
*
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 09 Feb 2021 Status changed from active, no longer recruiting to discontinued as Eisai agreed to voluntarily withdraw Belviq XR from US market.
- 19 Dec 2019 Planned End Date changed from 26 Jan 2021 to 11 Dec 2020.
- 19 Dec 2019 Planned primary completion date changed from 26 Jan 2021 to 11 Dec 2020.